4 results about "Cardiac ischemia" patented technology

This invention discloses an intestinal fungus Saccharomyces cerevisiae M7015 and its applications belong to the field of microbial technology. Saccharomyces cerevisiae The accession number for M7015 is GDMCC No. 66195. This invention first demonstrated, using a mouse subcutaneous stroma embolism model, that the aforementioned strain can promote angiogenesis; secondly, using mouse and Bama miniature pig myocardial infarction models, it was found that the aforementioned strain can promote collateral angiogenesis in ischemic areas of the heart and improve cardiac function. This invention not only fully elucidates... Saccharomyces cerevisiae M7015 promotes the formation of collateral vessels in the heart and improves cardiac function, and also reveals the broad application prospects of this bacterium in the treatment of vascular diseases.

The application discloses application of Piancizhu in preparation of a medicine for preventing and / or treating myocardial infarction. The application first discovers that Piancizhu can play an anti-cardiac ischemic injury role by improving heart function of a mouse model of left anterior descending branch stenosis of coronary artery, inhibiting inflammation levels of a heart, peripheral blood and bone marrow after cardiac infarction, reducing a myocardial infarction area and improving cardiac function disorder. Therefore, the application provides a scientific basis for increasing a clinical treatment indication of Piancizhu in acute myocardial infarction, simultaneously provides a new drug selection for clinical treatment of an acute cardiac infarction patient due to a good anti-inflammatory effect, and has a good application prospect.

A cardiac-targeting extracellular vesicle (EV), an EV for treating cardiovascular disease, and method of preparation and use thereof are provided. The EV contains a fusion sequence of Lamp-2b and peptide targeting cardiacmyocytes, CMP. It has been discovered that the cardiac-targeting EV exhibits the ability to specifically target the heart, thereby serving as a novel delivery tool system for cardiac-targeting therapy. The cardiac-targeting EV is loaded with miR-30d to obtain an EV for treating the cardiovascular disease, which demonstrates significant therapeutic effects on conditions such as cardiac ischemia-reperfusion injury and myocardial hypertrophy. This provides a new therapeutic approach for the clinical treatment of cardiovascular diseases. Additionally, targeted delivery of therapeutic agents using the cardiac-targeting EV is achieved, enabling effective prevention and treatment of cardiac diseases.

The present invention relates to pharmaceutical compositions for oral administration of A3R agonist compounds. The compositions are designed to disintegrate or disperse rapidly to deliver an effective dose of the compound for treating, ameliorating, or promoting recovery from certain conditions of the brain, central nervous system (CNS), or cardiovascular system such as a brain injury, a neurodegenerative condition, or cardiac ischemia.